Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsing Forms of MS”

36 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 36 results

Post-approval studies (Phase 4)Ended earlyNCT02241785
What this trial is testing

Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies

Who this might be right for
Relapsing Multiple Sclerosis
Biogen 47
Post-approval studies (Phase 4)Study completedNCT02307838
What this trial is testing

Long-term Follow-up of Fingolimod Phase II Study Patients

Who this might be right for
Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
Novartis Pharmaceuticals 177
Testing effectiveness (Phase 2)Ended earlyNCT00484536
What this trial is testing

Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Who this might be right for
Multiple Sclerosis
UCB Pharma 232
Large-scale testing (Phase 3)Study completedNCT02980042
What this trial is testing

Safety of Switching From Rituximab to Ocrelizumab in MS Patients

Who this might be right for
Multiple Sclerosis
University of Colorado, Denver 200
Not applicableStudy completedNCT01281657
What this trial is testing

Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program

Who this might be right for
Multiple Sclerosis
Novartis 64
Not applicableStudy completedNCT01592097
What this trial is testing

Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS

Who this might be right for
Multiple Sclerosis
University of Southern California 51
Large-scale testing (Phase 3)Study completedNCT01199861
What this trial is testing

Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)

Who this might be right for
Relapsing Multiple Sclerosis
Novartis 138
Not applicableStudy completedNCT01070836
What this trial is testing

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab

Who this might be right for
Relapsing Multiple Sclerosis
Biogen 35,895
Testing effectiveness (Phase 2)Ended earlyNCT01950234
What this trial is testing

ACTH in Progressive Forms of MS

Who this might be right for
Secondary Progressive Multiple SclerosisPrimary Progressive Multiple SclerosisProgressive Relapsing Multiple Sclerosis
University of Minnesota 59
Early research (Phase 1)Ended earlyNCT01144351
What this trial is testing

A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Elan Pharmaceuticals 32
Post-approval studies (Phase 4)Study completedNCT03784898
What this trial is testing

Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada

Who this might be right for
Multiple Sclerosis
Genzyme, a Sanofi Company 13
Post-approval studies (Phase 4)Study completedNCT03135249
What this trial is testing

Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis (MS)
University of Texas Southwestern Medical Center 9
Very early researchStudy completedNCT00424788
What this trial is testing

Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)

Who this might be right for
Relapsing Forms of Multiple Sclerosis
Biogen 12
Testing effectiveness (Phase 2)Study completedNCT00109161
What this trial is testing

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
PDL BioPharma, Inc. 270
Post-approval studies (Phase 4)Study completedNCT03589105
What this trial is testing

Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting

Who this might be right for
Multiple Sclerosis
Hoffmann-La Roche 423
Post-approval studies (Phase 4)Looking for participantsNCT06444113
What this trial is testing

Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Novartis Pharmaceuticals 20
Large-scale testing (Phase 3)Study completedNCT00472797
What this trial is testing

Rebif New Formulation (RNF) Quality of Life (QOL) Study

Who this might be right for
Relapsing Multiple Sclerosis
EMD Serono 232
Not applicableEnded earlyNCT04746976
What this trial is testing

Study of Diroximel Fumarate in the Real-World Setting

Who this might be right for
Relapsing Forms of MS
Biogen 75
Not applicableUnknownNCT00914758
What this trial is testing

Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Washington Neuropsychology Research Group 1
Not applicableStudy completedNCT00464074
What this trial is testing

Evaluation of Natalizumab for thE Relief of MS Associated FatiGue

Who this might be right for
Multiple Sclerosis
Biogen 89
Load More Results